Synchronous kinetics of CD4+ lymphocytes and viral load before the onset of oral candidosis and hairy leukoplakia in a cohort of Mexican HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 21, Issue 12, 2005, Pages 981-990

  Ramírez Amador, Velia ^a   Ponce De León, Sergio ^b   Sierra Madero, Juan ^b   Soto Ramírez, Luis ^b   Esquivel Pedraza, Lilly ^b   Anaya Saavedra, Gabriela ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MEXICO; MOUTH EXAMINATION; PRIORITY JOURNAL; TERTIARY HEALTH CARE; THRUSH; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOPLAKIA, HAIRY; MALE; MEXICO; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 30344471058     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.981     Document Type: Article

References (37)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
2. Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannanta SW, and Axell TE: Prognostic significance of HIV-associated oral lesions and their relation with therapy. Oral Dis 2002;8(Suppl. 2):110-114.
3. Greenspan JS: Sentinels and signposts: The epidemiology and significance of the oral manifestations of HIV disease. Oral Dis 1997;3(Suppl. 1):13-17.
4. Greenspan JS and Greenspan D: The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002;8(Suppl. 2):34-39.
5. Kerdpon D, Pongsiriwet S, Pangsomboon K, et al.: Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Dis 2004;10:138-144.
6. + cell count and viral load in an Italian study population. J Oral Pathol Med 1999;28:173-177.
7. Patton LL, McKaig RG, Eron Jr JJ, Lawrence HP, and Strauss RP: Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. AIDS 1999;13:2174-2176.
8. Greenspan D, Komaroff E, Redford M, et al.: Oral mucosal lesions and HIV viral load in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr 2000;25:44-50.
9. Margiotta V, Campisi G, and Mancuso S: Plasma HIV-1 RNA and route of transmission in oral candidiasis and oral hairy leukoplakia. Oral Dis 2000;6:194-195.
10. Patton LL: Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:182-188.
11. Campisi G, Pizzo G, Mancuso S, and Margiotta V: Gender differences in human immunodeficiency virus-related oral lesions: An Italian study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:546-551.
12. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, et al.: Oral clinical markers and viral load in a prospective cohort of Mexican HIV-infected patients. AIDS 2001;15:1910-1911.
13. Campo J, Del Romero J, Castilla J, García S, Rodríguez C, and Bascones A: Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002;31:5-10.
14. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, and Ponce-de-Leon S: The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients. A twelve-year study in a referral center in Mexico. Medicine 2003;82:39-50.
15. Greenspan D, Gange SJ, Phelan JA, et al.: Incidence of oral lesions in HIV-1-infected women: Reduction with HAART. J Dent Res 2004;83:145-150.
16. Nicolatou-Galitis O, Velegraki A, Paikos S, et al.: Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004;10:145-150.
17. EC-Clearinghouse on oral problems related to HIV infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus: Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993;22:289-291.
18. Yeni PG, Hammer SM, Carpenter CCJ, et al.: Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.
19. Matthews LNS, Altman DG, Campbell MJ, and Royston P: Analysis of serial measurements in medical research. Br Med J 1990;300:230-235.
20. StataCorp.2001: Stata Statistical Software: Release 7.0. Stata Corporation, College Station, TX.
21. Morgan D, Mahe C, Mayanja B, et al.: Progression of symptomatic disease in people infected with HIV-1 in rural Uganda: A prospective cohort study. Br Med J 2002;324:193-197.
22. Carré N, Boufassa F, Hubert JB, et al.: Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/μL. Int J Epidemiol 1998;27:897-903.
23. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-938.
24. + cell count. JAMA 1998;279:35-40.
25. + cells per cubic millimeter. AIDS Res Hum Retroviruses 2000;16:645-653.
26. Geskus RB, Miedema FA, Goudsmit J, Reiss P, Schuitemaker H, and Coutinho RA: Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr 2003;32:514-521.
27. + T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy. The Aquitaine cohort. J Acquir Immune Defic Syndr 2003;33:380-386.
28. Secretaría de Salud, Centro Nacional para la Prevención y Control del VIH/SIDA (CENSIDA): Panorama epidemiológico del VIH/SIDA e ITS en México. México: SSA/CENSIDA. (Available at: http://www.salud.gob.mx/conasida/comite/estadis.htm.) Accessed May 26, 2005.
29. Hilton JF, Donegan E, Katz MH, et al.: Development of oral lesions in human immunodeficiency virus-infected transfusion recipients and hemophiliacs. Am J Epidemiol 1997;145:164-174.
30. Lifson AR, Hilton JF, Westenhouse JL, et al.: Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts. AIDS 1994;8:73-79.
31. Patton LL and Shugars DC: Immunologic and viral markers of HIV-1 disease progression: Implications for dentistry. J Am Dent Assoc 1999;130:1313-1322.
32. Ho DD: Perspectives series: Host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J Clin Invest 1997;99:2565-2567.
33. Centers for Disease Control and Prevention: 1993 Revised Classification System for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
34. Anonymous: Development of antiretroviral therapy in Africa. Trial summary. (Available at: http://www.ctu.mrc.ac.uk/dart/summary.asp.) Accessed May 26, 2005.
35. Reid A, Munderi P, Kityo C, et al.: A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa: The DART trial. XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand, abstract TuPeB4495.
36. Crowe S, Turnbull S, Oelrichs R, and Dunne A: Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003;37(Suppl. 1):13-24.
37. Mekonnen Y, Dukers NHTM, Sanders E, et al.: Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 2003;17:815-819.